Company news

Lantheus Holdings, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Lantheus Holdings to Host Third Quarter 2021 Earnings Conference Call and Webcast on November 4, 2021 at 8: 00 a.m. Eastern Time

October 20, 2021

Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network® (NCCN) Guidelines for Prostate Cancer

September 12, 2021

Lantheus and RefleXion Announce Development and Commercialization Collaboration with the Potential to Improve Future Prostate Cancer Treatment

September 12, 2021

Lantheus Announces Presentation at the 2021 American Urological Association (AUA) Annual Meeting

September 9, 2021

Lantheus Announces the First and Only FDA Cleared AI-Enabled PSMA Digital Application, aPROMISE™, Strengthening Lantheus’ Leadership in Prostate Cancer

July 28, 2021

Lantheus Holdings, Inc. Reports Second Quarter 2021 Financial Results

July 27, 2021

Lantheus Holdings to Host Second Quarter 2021 Earnings Conference Call and Webcast on July 28, 2021 at 8: 00 a.m. Eastern Time

July 13, 2021

Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting

June 13, 2021

Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer

May 26, 2021

Lantheus Holdings Announces Presentation Featuring ¹⁸F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting

May 20, 2021

Lantheus Holdings to Present at the Jefferies Virtual Healthcare Conference

May 19, 2021

Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results

May 3, 2021

EXINI Diagnostics AB, a Lantheus Company, Receives CE Mark Clearance for aPROMISE in Europe

May 2, 2021

Lantheus Grants Allegheny Health Network Exclusive Rights for the Use of its Microbubbles in Combination with Ultrasound Assisted Gene Therapy for the Development of a Proposed Treatment for Xerostomia

April 29, 2021

Lantheus Holdings to Host First Quarter 2021 Earnings Conference Call and Webcast on May 4, 2021 at 8: 00 a.m. Eastern Time

April 19, 2021

Lantheus Expands R&D Leadership Team with Key New Hires

April 6, 2021

Lantheus Announces Retirement of Michael P. Duffy, Senior Vice President and General Counsel

March 31, 2021

Lantheus Acquires Rights to Innovative Imaging Biomarker Targeting Fibroblast Activation Protein (FAP) from Noria

March 29, 2021

Lantheus Announces Presentation Featuring AZEDRA® (iobenguane I 131) at ENDO 2021

March 21, 2021

Lantheus Announces Publication of PyL™ (18F-DCFPyL) Results from Pivotal Studies

February 28, 2021

Lantheus Reports Fourth Quarter and Full Year 2020 Financial Results

February 24, 2021

Lantheus Holdings to Present at the 10th Annual SVB Leerink Global Healthcare Conference

February 11, 2021

Lantheus Holdings to Host Fourth Quarter and Full Year 2020 Earnings Conference Call and Webcast on February 25, 2020 at 4: 30 p.m. Eastern Time

February 10, 2021

Lantheus Holdings Announces Presentations Featuring its PSMA-Targeted Pipeline Product Candidates at the 2021 ASCO GU Annual Meeting

February 3, 2021

Lantheus Holdings Announces Submission of Drug Master File for NM-01 in the U.S.

January 11, 2021

PyL™ (18F-DCFPyL), Lantheus’ PSMA-Targeted Prostate Cancer Imaging Agent, to be Used in POINT Biopharma’s PSMA-Targeted Radioligand Therapeutic Phase 3 Trial in Patients with Metastatic Castration Resistant Prostate Cancer

December 8, 2020

Lantheus Holdings Announces Acceptance and Priority Review of New Drug Application for PyLTM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer PET Imaging Agent

December 8, 2020

Lantheus Holdings, Inc. Announces Agreement to Sell Its Puerto Rico Radiopharmacy and PET Manufacturing Facility and Enter into Long-Term Supply Agreement

December 2, 2020

Lantheus Holdings to Present at the 2020 Evercore ISI HealthCONx Conference

November 23, 2020

Lantheus Holdings, Inc. Announces FDA Approval of DEFINITY® Room Temperature

November 17, 2020

Lantheus Holdings Announces FDA Clearance for AI-Enabled Automated Bone Scan Index (aBSI) in Prostate Cancer on GE Healthcare’s Xeleris Platform

November 12, 2020

CORRECTION: TIME CHANGE - Lantheus Holdings to Present at November 2020 Investor Conferences

November 8, 2020

Lantheus Holdings, Inc. Reports Third Quarter 2020 Financial Results

November 4, 2020

Lantheus Holdings to Present at November 2020 Investor Conferences

November 3, 2020

Lantheus Enters into Strategic Collaboration with Insightec for Use of Microbubbles in Combination with MR-Guided Focused Ultrasound for Treatment of Glioblastoma and Neurodegenerative Conditions

October 28, 2020

Lantheus Holdings to Host Third Quarter 2020 Earnings Conference Call and Webcast on November 5, 2020 at 8: 00 a.m. Eastern Time

October 21, 2020

Lantheus Holdings Announces Presentations at the 33rd Annual European Association of Nuclear Medicine (EANM) Virtual Congress

October 7, 2020

Lantheus Holdings Submits New Drug Application to the U.S. FDA for PyL™ (18F-DCFPyL), a PSMA-Targeted Prostate Cancer Imaging Agent

September 29, 2020

Lantheus Holdings to Present at the Wells Fargo 2020 Virtual Healthcare Conference

September 2, 2020

Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY®

August 11, 2020

Lantheus Holdings, Inc. Reports Second Quarter 2020 Financial Results

July 29, 2020

Lantheus Holdings to Host Second Quarter 2020 Earnings Conference Call on July 30, 2020 at 8: 00 a.m. Eastern Time

July 22, 2020

Lantheus Holdings to Showcase the Potential of PyL™ Imaging Agent at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting

June 30, 2020

Lantheus Completes Merger with Progenics

June 21, 2020

Lantheus Stockholders Approve Share Issuance For Merger with Progenics

June 15, 2020

Lantheus Holdings, Inc. Reports First Quarter 2020 Financial Results

April 29, 2020

Lantheus Holdings, Inc. Reports Preliminary Q1 Revenue Near Top End of Previously Disclosed Guidance Range; Withdraws 2020 Financial Guidance

April 8, 2020

Lantheus Holdings, Inc. to Hold 2020 Annual Meeting of Stockholders Virtually

April 5, 2020

Lantheus and Progenics Reschedule Their Respective Special Meetings of Stockholders for Proposed Merger

April 1, 2020

Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results

February 24, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 17 decks. Every deck is listed under its year.